KPC (derived) Syngeneic Model Service for Pancreas Cancer

The KPC (derived) syngeneic model of pancreas cancer transplants tumor cells carrying the endogenous Kras^G12D and Trp53^R172H drivers into immunocompetent C57BL/6 hosts, combining human-relevant PDAC genetics with the control of an implantable system. Alfa Cytology delivers the complete KPC-derived workflow—genotype-verified cell banking, subcutaneous, orthotopic, fragment or intrasplenic implantation, balanced randomization, scheduled dosing and stroma- and metastasis-inclusive endpoint analysis—giving sponsors decision-ready preclinical datasets shaped to their program, strictly within a preclinical scope.

Overview of KPC (derived) Syngeneic Model for Pancreas Cancer

The KPC lineage begins with a genetically engineered mouse that changed pancreatic cancer research: Pdx1-Cre; LSL-Kras^G12D; LSL-Trp53^R172H animals (Hingorani and colleagues, 2005) develop pancreatic intraepithelial neoplasia that progresses to invasive, metastatic PDAC with dense desmoplasia and effector-T-cell exclusion—a genetic pairing that mirrors human disease, where KRAS is mutated in the overwhelming majority and TP53 in roughly seventy percent of cases. The murine Trp53 R172H allele corresponds to the human R175H hotspot. Because spontaneous disease in the GEMM is powerful but variable in latency, the field distilled it into transplantable derivatives—cell lines such as FC1245 and FC1199 (backcrossed to C57BL/6 over ten generations), 7940B, MT-5 and luciferase-tagged variants—whose Kras and Trp53 recombined alleles are confirmed by genotyping PCR. The cells grow as loosely adherent, polygonal epithelial monolayers in DMEM with 10% serum, with published practice favoring early passages (six to twelve) and mycoplasma-negative certification.

Fig 1. Orthotopic bioluminescence imaging and tumor growth comparison of parental KPC versus KPC-Luc cells, revealing that firefly luciferase expression elicits an anti-tumor immune response—smaller or absent tumors with NK cell accumulation and increased CD8+ T-cell infiltration—an important caveat for luciferase-engineered syngeneic PDAC models. (Ferrari, Daniele Pereira, et al., 2024)

What distinguishes KPC-derived tumors is their microenvironment: abundant F4/80-positive macrophages, sparse CD3-positive T cells, and collagen-rich desmoplasia—though direct comparisons show that cell-line implants carry substantially less stroma than the parent GEMM, and that three-millimeter tumor-fragment orthotopic implants preserve the desmoplastic, leukocyte-rich architecture most faithfully. Format options map to questions: subcutaneous implants for routine efficacy; orthotopic parenchymal injection (one hundred thousand cells) where organ context matters, with aggressive courses reaching median survival near twenty-three days (KPC-Luc) versus thirty-six days (MT-5); fragment implants for stroma-question work; and intrasplenic delivery of half a million luciferase-tagged cells for liver-metastasis imaging at three weeks. The model has carried mechanistic breakthroughs—CD40 agonism reprogramming macrophages to degrade fibrosis and enhance gemcitabine efficacy, PIK3CA loss rendering tumors immunogenic through MHC-I and CD80 upregulation, and DHODH-inhibitor sensitivity mapping. Caveats: match the strain to the line’s documented background (some derivatives such as PDA530Met sit on mixed 129/C57BL stock)—and accept that cell-line formats trade away some desmoplasia, so stroma-centric hypotheses may demand fragment or GEMM-context designs.

Cell Line Information: KPC (derived)

Key characteristics of KPC-derived lines and their formats are summarized below.

Our Services

With in vivo oncology specialists guiding each stage and bioluminescence imaging, trichrome histology and immune-profiling capabilities in-house, Alfa Cytology molds every KPC-derived engagement around the sponsor’s question—selecting lines and formats that match the stroma and genetics being interrogated, enforcing genotyping and early-passage discipline, and pairing dosing with desmoplasia scoring, immune IHC and metastasis readouts for clean, decision-grade preclinical data.

Workflow of KPC (derived) Syngeneic Model Construction

Construction of the KPC-derived syngeneic model is an implantation workflow whose quality rests on genotype-verified, early-passage cells, strain-matched recipients, format-matched technique and a disciplined measurement cadence. A standard engagement proceeds as follows:

1. Source and qualify cells: KPC-derived stocks are cleared by mycoplasma testing, genotyped by PCR for the recombined Kras^G12D and Trp53^R172H alleles, kept within early passages (6–12 per published practice), and luciferase expression is titrated in vitro where imaging readouts are required.
2. Prepare recipients: C57BL/6J mice (typically 6–8 weeks old; strain matched to the line’s documented background) complete acclimation and health screening and are individually marked before implantation.
3. Prepare the inoculum: log-phase cells are harvested, washed, counted and resuspended in PBS (1 × 10⁶ cells in 100 µL for flank implants; 1 × 10⁵ cells in a small volume for orthotopic parenchymal injection; 5 × 10⁵ cells for intrasplenic delivery); 3 mm fragments are trimmed fresh for stroma-preserving formats.
4. Implant: cells are injected subcutaneously into the flank, into the pancreatic parenchyma under anesthesia with perioperative analgesia, into the spleen for the liver-metastasis format, or as fragments into the pancreas, with aseptic technique throughout.
5. Randomize: flank-format animals are grouped when tumors reach palpability, balanced by tumor volume and body weight; orthotopic, fragment and intrasplenic cohorts are randomized at implantation or at the first staging scan.
6. Dose and follow: test articles are administered on schedule; flank tumors are measured with calipers two to three times weekly, while orthotopic and metastatic cohorts are followed by body weight and weekly bioluminescence imaging; survival is recorded for orthotopic designs.
7. Terminate and analyze: tumors are resected and weighed; liver, lung and peritoneum are inspected for metastasis; desmoplasia is scored by trichrome staining; CD3, CD8 and F4/80 immunohistochemistry and flow cytometry profile the infiltrate; tissues enter histopathology and molecular analysis.

Fig 2. KPC (derived) Syngeneic Model construction workflow.

Case Study-KPC (derived) Syngeneic Model Development

Alfa Cytology keeps an active file of preclinical case studies on the KPC-derived platform: establishment-phase genotype verification and format selection, in vivo growth tracking by caliper or bioluminescence, KRAS-, stroma- and immune-focused intervention studies, and systematic endpoint analyses covering desmoplasia scoring, immune infiltration and liver-metastasis burden. Representative growth curves, imaging series and endpoint summaries can be shared upon request and will be updated as new programs conclude.

Why Choose Alfa Cytology?

KPC-derived work succeeds on genetic fidelity, strain matching and format honesty—exactly where Alfa Cytology concentrates its effort:

• Genotype-verified, early-passage banking with documented Kras and Trp53 PCR confirmation.
• Strain-matched execution honoring each line’s C57BL/6 or mixed-background provenance.
• Format breadth spanning subcutaneous, orthotopic, fragment and intrasplenic implants.
• Stroma-aware endpoint design using trichrome and macrophage/T-cell IHC when desmoplasia matters.
• CD40-agonist and stroma-program familiarity reflecting the model’s mechanistic literature.
• Aggressive-course scheduling with humane endpoints defined for orthotopic designs.
• One accountable project contact with milestone-by-milestone visibility.
• A strictly preclinical scope—every study is planned, executed and reported as non-clinical research.

Contact Us

Interested in the KPC-derived syngeneic pancreas cancer model for your next preclinical program? Reach out to us with your agent, timeline and endpoint wish-list, and the Alfa Cytology team will respond with a customized plan covering model setup, dosing strategy and analysis workflow—contact us today and move your program forward with confidence.

For research use only. Not intended for any clinical use.